Vigonvita Life Sciences Co., Ltd. (hereinafter referred to as “Vigonvita”), founded in 2013, was listed on the Hong Kong Stock Exchange in November 2025, with the stock code 2630.HK.
Vigonvita is an innovation-driven biopharmaceutical company committed to improving patient health and quality of life. Vigonvita focuses on pioneering new drug development in the fields of viral infections, neuropsychiatry, and reproductive health. Vigonvita has established a fully integrated and internally controlled system covering the entire industrial chain—from lead discovery, drugability evaluation, and preclinical studies to clinical research, manufacturing, and commercialization—enabling the rapid and efficient translation of lead compounds from laboratory research to clinical application.
Vigonvita has established a highly competitive and diversified pipeline of innovative drugs. Among these, two innovative drugs have reached the commercialization stage, five drug candidates are in clinical trials, and two candidate compounds are in the preclinical research stage.
VV116 is an oral nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor with broad-spectrum antiviral potential. Its tablet formulation for COVID-19 has been approved for marketing in China (brand name: 民得維®) and Uzbekistan (brand name: Mindvy®). A Phase II clinical trial for its dry suspension formulation targeting respiratory syncytial virus (RSV) infection in infants and young children has been completed and showed positive results. Based on this, Deuremidevir Hydrobromide (VV116) Dry Suspension has been included in the list of Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA).
TPN171 is a novel, highly active, and highly selective PDE5 inhibitor. Its tablet formulation for erectile dysfunction has been approved for marketing in China (brand name: 昂偉達®) and Uzbekistan (brand name: Onvita®).
Vigonvita (Lianyungang) Pharmaceutical Co., Ltd., a subsidiary of Vigonvita, has established an active pharmaceutical ingredient (API) and drug product manufacturing system that complies with both domestic and international GMP standards and EHS (Environment, Health, and Safety) requirements. This includes a versatile and modular emergency production platform capable of sustaining routine drug production and being rapidly reconfigured during emergencies. This infrastructure provides crucial support and ensures supply for the R&D, technological translation, and production of pharmaceuticals targeting emerging and sudden viral infections.
Vigonvita will continue to uphold its philosophy of innovation-driven development, deepening its commitment to the fields of viral infections, neuropsychiatry, and reproductive health. Vigonvita is dedicated to alleviating patients’ suffering and creating meaningful value for society.
Vigonvita is headquartered in Suzhou and has established R&D centers in both Suzhou and Shanghai. The company operates an active pharmaceutical ingredient and drug product manufacturing facility in Lianyungang, Jiangsu Province. In Uzbekistan, Vigonvita has set up its subsidiary, Vigonvita Tashkent, responsible for product registration, regulatory submissions, and sales in the local market. To date, two of the company’s products have been approved for marketing in Uzbekistan. Building on this foundation, Vigonvita is further expanding its business into other countries, including North Africa, Central Asia, the Middle East, and Russia.
Guanghui Tian PhD, Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Responsible for overall strategic planning, business guidance, and operational management, with over 20 years of industry experience.
Appointed as an Industry Professor by Soochow University and recognized as a ” key industry urgently-needed talents” by government authorities.
As the leader or participated in a number of national scientific research projects, such as Major Science and Technology Special Project for “Significant New Drugs Development” (“重大新藥創制”科技重大專項) and the National High-tech R&D Program (“863 Program”).
Zhiqiang Wang PhD, Chinese Pharmaceutical University
Suzhou “Gusu Innovative Leading Talents”
More than 20 years of experience in R&D, clinical trial and registration of innovative drugs
Hosted and participated in 6 national major projects such as “863 Program” and “Innovative Drug Creation ”
Awarded “Second Prize of of China Pharmaceutical Society Science and Technology Award”, “First Prize of Shanghai Pharmaceutical Science and Technology Award”, “Third Prize of Jiangsu Scientific and Technological Progress” and other honors
Tianwen Hu PhD, Xinjiang Technical Institute of Physics and Chemistry , Chinese Academy of Sciences
Years of experience in innovative drug development,has published more than 20 Science Citation Index (SCI) research papers.
and participated in a number of provincial science and technology projects as project leaders or core members.
Played an important role in the development of the anti-new coronavirus drug VV116
2022 National Key R&D Program —— Clinical Study of VV116, a New Oral Anti-New Coronavirus Drug, in “BRI” Countries
2021 National Key Research and Development Program —— Clinical Study of VV116, a New Oral Nucleoside Anti-New Coronavirus Drug Candidate
2019 The State Scientific and Technological Major Project “Creation of Key Innovative Drug” —— Registration and Marketing of Anti-Hepatitis C Drug Sofosbuvir in Central Asia
2019 “BRI” International Union of Scientific Organizations Anti-epidemic Special Project —— China-Uzbekistan Joint Anti-New Coronavirus Infection Emergency Drug Research and Development
2018 National “Creation of Key Innovative Drugs” Scientific and Technological Major Program —— Research and Development of New Small Molecule Drugs with New Targets and Their Key Innovative Technology System
2022 Special Funds for Science and Technology Programs in Jiangsu Province (Key R&D Program for Social Development) —— Phase I Clinical Study of VV116, an Emergency Drug Against New Coronavirus Infections
2021 Suzhou Technology Transfer System Construction Project —— Anti-Epileptic Class 1 Innovative Drug TPN102
2020 Suzhou Technology Transfer System Construction Project —— R&D and industrialization of TPN171, a new anti-pulmonary arterial hypertension class 1 drug
2019 Jiangsu Province Industry-University-Research Collaboration Program —— Clinical Study of TPN171, a New Class 1 Drug against Pulmonary Arterial Hypertension
2019 Jiangsu Province Policy Guidance Program (International Science and Technology Cooperation) —— Collaborative Development and Overseas Application Demonstration of Innovative and Special Drugs in Central Asia
2017 Passed ISO9001:2015-Quality Management System Certification
2024 Passed ISO14001:2015-Environmental Management System Certification
2024 Passed ISO45001:2018-Occupational Health and Safety Management System Certification
